NCT05909488View on ClinicalTrials.gov

Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

December 1, 2027

Conditions
Retinitis Pigmentosa
Interventions
BIOLOGICAL

1.5 x 10^6 UC-MSC + CM

1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)

BIOLOGICAL

5 x 10^6 UC-MSC + CM

5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)

Trial Locations (1)

55284

RSUP Dr. Sardjito, Yogyakarta

All Listed Sponsors
lead

PT. Prodia Stem Cell Indonesia

INDUSTRY

NCT05909488 - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II | Biotech Hunter | Biotech Hunter